Natera (NTRA) Resumen de Acciones
Natera, Inc. es una empresa de diagnóstico que se dedica al desarrollo y comercialización de servicios de pruebas moleculares en todo el mundo. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 2/6 |
| Crecimiento futuro | 4/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 6/6 |
| Dividendos | 0/6 |
NTRA Community Fair Values
Create NarrativeSee what 44 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
Read full narrativeCompetidores de Natera, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$219.82 |
| Máximo en las últimas 52 semanas | US$256.36 |
| Mínimo de 52 semanas | US$131.81 |
| Beta | 1.57 |
| Cambio en 1 mes | 5.04% |
| Variación en 3 meses | 8.26% |
| Cambio de 1 año | 35.22% |
| Variación en 3 años | 325.84% |
| Variación en 5 años | 147.21% |
| Variación desde la OPV | 866.67% |
Noticias y actualizaciones recientes
Recent updates
NTRA: MRD Leadership And New Genomic Offering Will Support Long-Term Trajectory
Analysts have kept their $300 price target on Natera unchanged, while slightly adjusting assumptions for discount rate, revenue growth, profit margins and future P/E after a mix of recent research that includes both modest target cuts and higher targets tied to updated models, guidance and a generally constructive view on the stock. Analyst Commentary Recent research paints a generally constructive picture of how Wall Street views Natera, with multiple bullish analysts fine tuning their models around updated guidance, P/E assumptions and profitability paths.
NTRA: Oncology Execution And 2026 Catalysts Will Shape Fairly Valued Outlook
Analysts have trimmed the blended price target for Natera by about $2 to reflect updated models that incorporate slightly higher discount rates, revised revenue growth and profit margin assumptions, and a lower future P/E multiple, while still indicating constructive views from recent research coverage. Analyst Commentary Recent research on Natera presents a mix of supportive long term views and valuation recalibrations, with several firms updating models after quarterly results and competitive developments in genetic testing.
NTRA: Molecular Residual Disease Leadership Will Drive Bullish Long Term Outlook
Analysts made a modest trim to the blended price target on Natera to about $259, reflecting slightly lower modeled revenue growth and profit margins. This adjustment comes even as several firms recently raised individual targets into the $215 to $300 range after updating their views on the company following Q4 results and new coverage initiations.NTRA: Molecular Residual Disease Leadership And Genomics Launch Will Shape Future Outlook
The analyst fair value estimate for Natera has been adjusted modestly higher from $257.20 to $260.65, reflecting updated models that incorporate recent Street price target revisions and assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Street research around Natera has centered on how the company executes on its current guidance, maintains its position in key testing markets, and justifies premium valuation multiples through future growth and margin delivery.Natera Looks Compelling As Oncology Testing Momentum Keeps Building
Summary NTRA’s oncology franchise, led by Signatera MRD testing, is the main bull case at this point. As long as they keep building on their testing volumes, I believe this should support a long runway in cancer monitoring and recurrence detection. NTRA’s 2025 also included new product launches and added Medicare coverage, advanced early cancer detection, and broadened its molecular diagnostics portfolio. Their Foresight acquisition also strengthens NTRA’s MRD moat through PhasED-Seq technology, better testing sensitivity, and taps into lymphoma screening. I reckon NTRA’s valuation multiples are expensive. However, I think their current growth rate with Signatera justifies its price tag, which is why I lean bullish. Read the full article on Seeking AlphaNTRA: Elevated Oncology And 2026 Catalyst Hopes Will Likely Cap Future Upside
The updated analyst price target for Natera edges higher to a fair value estimate of $208.44 from $194.59, reflecting recent Street research where several firms lifted their targets following Q4 results, improved gross margin commentary, and expectations for a catalyst rich 2026. Analyst Commentary Recent Street research on Natera points to a mixed backdrop, with a cluster of higher price targets sitting well above the updated fair value estimate of $208.44, but also some signs of restraint as models are refreshed after Q4 results and initial 2026 guidance.NTRA: MRD Leadership And Broad Test Portfolio Will Support Long-Term Trajectory
Narrative Update on Natera Analysts have refreshed their views on Natera with price targets now reaching up to $300. This is supported by expectations for solid sector results, confidence in the company’s position across women's and organ health, and its growing role in the molecular residual disease market.NTRA: Molecular Residual Disease Leadership And FDA Progress Will Shape Future Outlook
Analysts have raised their fair value estimate for Natera to about $257 from roughly $235, citing higher assumed revenue growth, improved profit margins, and Street research that highlights the company as an established diagnostics player with a strong position in molecular residual disease, along with multiple recent price target increases up to $300. Analyst Commentary Recent Street research has been broadly constructive on Natera, with several bullish analysts lifting their price targets and emphasizing the company’s role in diagnostics and molecular residual disease.NTRA: Expanding MRD Adoption And New Data Will Support Long-Term Trajectory
Analysts have lifted their Natera price targets into a US$220 to US$300 range, citing recent earnings beats, raised estimates, and what they describe as strong fundamentals and a long growth runway across diagnostics and molecular residual disease testing. Analyst Commentary Recent Street research points to a cluster of higher Natera price targets, with several bullish analysts citing what they view as strong execution in diagnostics and molecular residual disease testing.NTRA: Expanding MRD Adoption And Trials Will Support Long-Term Revenue Trajectory
Analysts have raised their fair value estimate for Natera to $300 from $285, citing a series of higher Street price targets and ongoing enthusiasm around the company's position in women's and organ health and the molecular residual disease market. Analyst Commentary Bullish analysts have been resetting their expectations higher, with a series of price target revisions in recent months that cluster in the US$210 to US$300 range.NTRA: Expanding Oncology Diagnostics Will Drive Stronger Long-Term Revenue Trajectory
The analyst fair value estimate for Natera has been raised to $285 from $268, as analysts factor in stronger anticipated revenue growth and sustained momentum in key diagnostics franchises, reflected in a series of higher Street price targets. Analyst Commentary Bullish analysts have recently raised their price targets on Natera across the board, citing stronger than expected execution and a robust outlook for revenue growth.NTRA: Elevated Expectations Around Oncology Expansion Will Likely Constrain Future Share Returns
Natera's analyst fair value estimate has been raised sharply from approximately $115 to about $195 per share, reflecting analysts' higher long term revenue growth assumptions and confidence following a series of recent price target increases across the Street. Analyst Commentary Recent Street research has been predominantly constructive on Natera, with multiple firms lifting price targets into the $200 to $280 range and reiterating positive ratings.NTRA: Recent Clinical Results And Competitive Position Will Influence Future Outlook
Natera's analyst price target has been raised to $234.68 from $222.58. Analysts cite ongoing strong revenue performance, increased growth expectations, and recent research milestones as the primary drivers for the upward revision.NTRA: Recent Clinical Results And Cash Flow Risks Will Shape Future Performance
Natera's analyst price target has increased significantly from $202.50 to $222.58. This reflects analysts' optimism following raised estimates and expectations for continued growth, in light of recent positive clinical trial updates and industry leadership.Clinical Advances and AI Will Drive Expansion Into New Diagnostic Markets
Analysts raised their fair value estimate for Natera to $202.50 from $193.80. They cited momentum from recent clinical developments, positive trial updates, and ongoing strength in the company’s diagnostic and oncology business lines.Molecular Diagnostics And AI Integration Will Unlock New Market Opportunities
Analysts lowered Natera’s price target modestly to $193.80 as continued optimism around its liquid biopsy leadership and growth opportunities was tempered by renewed concerns about elevated valuation and margin outlook. Analyst Commentary Bullish analysts note Natera's leadership in liquid biopsy testing and large addressable markets in prenatal, minimal residual disease, and potential cancer screening, supporting long-term double-digit revenue growth.Molecular Diagnostics And AI Integration Will Unlock New Market Opportunities
Analysts raised Natera’s price target slightly to $198.45, citing strong Q2 results, continued leadership in liquid biopsy, robust pipeline momentum, and increasing market opportunities in cancer screening and prenatal testing. Analyst Commentary Bullish analysts cited Natera's solid Q2 beat, with significant revenue upside and sustained business momentum, leading to raised outlooks for 2025.Optimistic Investors Push Natera, Inc. (NASDAQ:NTRA) Shares Up 25% But Growth Is Lacking
Natera, Inc. ( NASDAQ:NTRA ) shares have had a really impressive month, gaining 25% after a shaky period beforehand...There's Reason For Concern Over Natera, Inc.'s (NASDAQ:NTRA) Price
Natera, Inc.'s ( NASDAQ:NTRA ) price-to-sales (or "P/S") ratio of 11.4x might make it look like a sell right now...Signatera, Prospera And Renasight Will Transform Diagnostics
Strong revenue growth driven by increased diagnostic volumes and strategic partnerships positively impacts Natera's earnings and future revenue potential.Rentabilidad de los accionistas
| NTRA | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 6.6% | 3.7% | 3.2% |
| 1Y | 35.2% | 41.9% | 31.0% |
Rentabilidad vs. Industria: Los resultados de NTRA fueron inferiores a los de la industria US Biotechs, que obtuvo un rendimiento del 41.9% el año pasado.
Rentabilidad vs. Mercado: NTRA superó al mercado US, que obtuvo un rendimiento del 31% el año pasado.
Volatilidad de los precios
| NTRA volatility | |
|---|---|
| NTRA Average Weekly Movement | 6.9% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Precio estable de las acciones: NTRA no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de NTRA (7%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2003 | 6,138 | Steve Chapman | www.natera.com |
Natera, Inc, empresa de diagnóstico, se dedica al desarrollo y comercialización de servicios de pruebas moleculares en todo el mundo. Ofrece Signatera, una prueba sanguínea personalizada de ctADN para la evaluación de la ERM, la monitorización de la recurrencia temprana y la evaluación de la respuesta al tratamiento en pacientes con diagnóstico previo de cáncer; Latitude, una prueba sanguínea de ERM para el cáncer colorrectal; Altera, una prueba de perfil genómico integral basada en tejidos; y Empower, una prueba de cribado del cáncer hereditario. La empresa también ofrece Panorama, una prueba prenatal no invasiva; Horizon, una prueba de detección de portadores; Fetal Focus, una NIPT de un solo gen, o sgNIPT, que detecta 21 afecciones hereditarias de un solo gen; y Vistara, una NIPT de un solo gen, que detecta 25 afecciones de un solo gen.
Resumen de fundamentos de Natera, Inc.
| Estadísticas fundamentales de NTRA | |
|---|---|
| Capitalización bursátil | US$30.71b |
| Beneficios(TTM) | -US$208.16m |
| Ingresos (TTM) | US$2.31b |
¿Está NTRA sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de NTRA | |
|---|---|
| Ingresos | US$2.31b |
| Coste de los ingresos | US$812.93m |
| Beneficio bruto | US$1.49b |
| Otros gastos | US$1.70b |
| Beneficios | -US$208.16m |
Últimos beneficios comunicados
Dec 31, 2025
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -1.46 |
| Margen bruto | 64.75% |
| Margen de beneficio neto | -9.03% |
| Ratio deuda/patrimonio | 4.7% |
¿Cómo se ha desempeñado NTRA a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/07 13:07 |
| Precio de las acciones al final del día | 2026/05/07 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Natera, Inc. está cubierta por 30 analistas. 18 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Luke Sergott | Barclays |
| Raymond Myers | Benchmark Company |